We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+17.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.6B
AUM Growth
+$255M
Cap. Flow
-$1.97M
Cap. Flow %
-0.08%
Top 10 Hldgs %
27.03%
Holding
158
New
8
Increased
60
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$19.4M
2
UNH icon
UnitedHealth
UNH
+$19.2M
3
WST icon
West Pharmaceutical
WST
+$14.7M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$12.2M
5
ARGX icon
argenx
ARGX
+$11.5M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.1M
2
AET
Aetna Inc
AET
+$40.4M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.5M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$9.19M
5
ZTS icon
Zoetis
ZTS
+$8.44M

Sector Composition

Rank Sector Weight
1 Healthcare 89.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$29.3B
$17.1M 0.66%
173,500
+30,500
+21% +$3.03M
LKFT
52
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$17.1M 0.66%
185,000
– –
OBSV
53
DELISTED
ObsEva SA Ordinary Shares
OBSV
$17M 0.65%
1,120,000
+280,000
+33% +$3.72M
JAZZ icon
54
Jazz Pharmaceuticals
JAZZ
$16.7B
$16.9M 0.65%
98,000
-25,700
-21% -$4.2M
EPZM
55
DELISTED
Epizyme, Inc
EPZM
$16.8M 0.65%
1,241,253
-33,747
-3% -$525K
BOLD
56
DELISTED
Audentes Therapeutics, Inc
BOLD
$16.8M 0.65%
440,000
-125,000
-22% -$4.63M
ARNA
57
DELISTED
Arena Pharmaceuticals Inc
ARNA
$16.4M 0.63%
375,000
– –
ASND icon
58
Ascendis Pharma A/S
ASND
$16.8B
$16.2M 0.62%
243,500
-40,000
-14% -$2.63M
HOLX
59
DELISTED
Hologic
HOLX
$15.9M 0.61%
400,000
– –
WST icon
60
West Pharmaceutical
WST
$24.9B
$15.9M 0.61%
+160,000
New +$14.7M
BHVN
61
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$15.7M 0.6%
397,500
+72,500
+22% +$2.3M
IDXX icon
62
Idexx Laboratories
IDXX
$46.2B
$15.7M 0.6%
72,000
+9,000
+14% +$1.85M
FOLD
63
DELISTED
Amicus Therapeutics
FOLD
$15.6M 0.6%
1,000,000
– –
BIIB icon
64
Biogen
BIIB
$30.7B
$15.4M 0.59%
53,000
– –
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$2.55B
$15.4M 0.59%
200,000
+27,000
+16% +$1.74M
XENT
66
DELISTED
Intersect ENT, Inc
XENT
$15.4M 0.59%
410,000
– –
TBPH icon
67
Theravance Biopharma
TBPH
$877M
$14.8M 0.57%
652,600
– –
GTHX
68
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$13M 0.5%
300,000
+13,000
+5% +$557K
EXEL icon
69
Exelixis
EXEL
$13.4B
$12.8M 0.49%
595,000
+420,000
+240% +$8.69M
TBIO
70
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$12.8M 0.49%
+1,011,079
New +$12.2M
BPMC
71
DELISTED
Blueprint Medicines
BPMC
$12.6M 0.49%
199,000
+41,247
+26% +$3.28M
AMRN
72
Amarin Corp
AMRN
$303M
$12.4M 0.48%
200,000
– –
PTLA
73
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$12.2M 0.47%
323,800
– –
IMMU
74
DELISTED
Immunomedics Inc
IMMU
$11.8M 0.46%
500,000
+50,000
+11% +$1M
MRTX
75
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.8M 0.46%
240,000
+51,000
+27% +$1.93M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rock Springs Capital Management held 158 positions worth $2.6B, up 11% from $2.34B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q2 2018 filing shows 8 new, 60 increased, 24 reduced and 11 closed positions. Its largest new stake was West Pharmaceutical: 160,000 shares worth $15.9M. The largest sale was Bristol-Myers Squibb, an estimated $41.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Financials.

  • Rock Springs Capital Management's largest Q2 2018 buy was West Pharmaceutical: 160,000 shares worth $15.9M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q2 2018, an estimated $19.4M increase.
  • Rock Springs Capital Management's biggest Q2 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $9.19M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $41.1M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $2.6B portfolio in Q2 2018.
  • Rock Springs Capital Management opened 8 new positions and closed 11 in Q2 2018.
  • Rock Springs Capital Management's portfolio value rose 11% quarter-over-quarter to $2.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.